FBLD2016 (Boston): Edelris will present positive results obtained with 3D fragments on Cyclophilin-D.

Key words: 3D fragments, fragment merging, Cyclophilin-D, outsourcing.

In the past 15 years, fragment-based drug discovery (FBDD) has delivered valuable starting points from the screening of relatively small sets of fragments and has been instrumental to the discovery of many clinical candidates.



3D-Keymical Fragment™

Innovation against new targets remains both desirable and challenging. Towards this aim, Edelris has developed innovative fragments maximizing topological diversity, pharmacophore display and synthetic tractability (Keymical Fragments™). Arguments that support the strong interest in 3D-fragments over traditionally flat heterocyclic structures will be illustrated by the positive results obtained on a FBLD collaborative program that led to the identification of a highly potent small molecule inhibitor of the peptidyl-prolyl isomerase Cyclophilin-D.